News & Publications
Featured News

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an…
See more
Acrivon Therapeutics

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
Acrivon Therapeutics

Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives
Acrivon Therapeutics

Acrivon Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
Acrivon Therapeutics

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
Acrivon Therapeutics

Acrivon Therapeutics to Present at the Evercore ISI HealthCONx Conference
Acrivon Therapeutics

Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
Acrivon Therapeutics

Acrivon Therapeutics Launches to Advance Clinical Oncology Pipeline Leveraging its Groundbreaking Precision Proteomics Platform

Events & Presentations

Oppenheimer 32nd Annual Healthcare Conference

Acrivon Presentation
Evercore ISI 4th Annual HealthCONx Conference

Acrivon presentation (Live 8am ET)

Media Highlights

Endpoints News

Acrivon bags a megaround to advance an old Eli Lilly program, 5 months after launch. Is an IPO far behind?
Fierce Biotech

Acrivon Therapeutics secures $100M to give Eli Lilly cancer drug another try, fund 2 solid tumor candidates
Boston Business Journal

With $100M, startup to bring Lilly-licensed drug into trials
Precision Oncology News

Acrivon Therapeutics Raises $100M in Series B Funding
Biospace

Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug
Biocentury

Crossovers back Acrivon in $100M series B
Endpoints News

Can a small band of biopharma players succeed where Eli Lilly failed? They’re taking a shot
BioCentury

Acrivon debuts with Lilly DDR inhibitor to test proteomics-based companion diagnostics platform
Boston Business Journal

Precision medicine startup launches with Eli Lilly deal and $20M in VC funds
Precision Oncology News

Eli Lilly Grants Acrivon Therapeutics Worldwide License to Develop DNA Damage Inhibitor Prexasertib